Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507788101> ?p ?o ?g. }
- W2507788101 endingPage "1142" @default.
- W2507788101 startingPage "1134" @default.
- W2507788101 abstract "Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta‐analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote‐counting method to perform a semiquantitative meta‐analysis of metabolites in tumor tissue and blood. This analysis confirmed well‐known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta‐analyses of CMP studies, calling for improved standardization of metabolomics studies.![][1] The results of clinical metabolic profiling studies in cancer were curated and a meta‐analysis was subsequently performed to identify deregulated metabolites in blood, tissue, and urine.EMBO Mol Med (2016) 8: 1134–1142 [1]: /embed/graphic-1.gif" @default.
- W2507788101 created "2016-09-16" @default.
- W2507788101 creator A5000233630 @default.
- W2507788101 creator A5005976916 @default.
- W2507788101 creator A5013924501 @default.
- W2507788101 creator A5016518691 @default.
- W2507788101 creator A5027967421 @default.
- W2507788101 creator A5034532090 @default.
- W2507788101 creator A5036342781 @default.
- W2507788101 creator A5047152113 @default.
- W2507788101 creator A5061761689 @default.
- W2507788101 creator A5090423367 @default.
- W2507788101 date "2016-09-06" @default.
- W2507788101 modified "2023-10-11" @default.
- W2507788101 title "Meta‐analysis of clinical metabolic profiling studies in cancer: challenges and opportunities" @default.
- W2507788101 cites W1509926796 @default.
- W2507788101 cites W1974438296 @default.
- W2507788101 cites W1979649481 @default.
- W2507788101 cites W1979729004 @default.
- W2507788101 cites W1995490493 @default.
- W2507788101 cites W1997062226 @default.
- W2507788101 cites W1998142996 @default.
- W2507788101 cites W2003605385 @default.
- W2507788101 cites W2023071064 @default.
- W2507788101 cites W2027157114 @default.
- W2507788101 cites W2046872827 @default.
- W2507788101 cites W2053991769 @default.
- W2507788101 cites W2069928158 @default.
- W2507788101 cites W2080452140 @default.
- W2507788101 cites W2081475551 @default.
- W2507788101 cites W2085923809 @default.
- W2507788101 cites W2086835855 @default.
- W2507788101 cites W2095987251 @default.
- W2507788101 cites W2097259163 @default.
- W2507788101 cites W2098064758 @default.
- W2507788101 cites W2110065044 @default.
- W2507788101 cites W2115944543 @default.
- W2507788101 cites W2118222200 @default.
- W2507788101 cites W2118258530 @default.
- W2507788101 cites W2123497942 @default.
- W2507788101 cites W2128831025 @default.
- W2507788101 cites W2132400619 @default.
- W2507788101 cites W2142856784 @default.
- W2507788101 cites W2155631120 @default.
- W2507788101 cites W2168735777 @default.
- W2507788101 cites W2170884400 @default.
- W2507788101 cites W2173728492 @default.
- W2507788101 cites W2178132220 @default.
- W2507788101 cites W2338627428 @default.
- W2507788101 cites W2401731207 @default.
- W2507788101 cites W4239960762 @default.
- W2507788101 cites W4253759977 @default.
- W2507788101 doi "https://doi.org/10.15252/emmm.201606798" @default.
- W2507788101 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5048364" @default.
- W2507788101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27601137" @default.
- W2507788101 hasPublicationYear "2016" @default.
- W2507788101 type Work @default.
- W2507788101 sameAs 2507788101 @default.
- W2507788101 citedByCount "71" @default.
- W2507788101 countsByYear W25077881012016 @default.
- W2507788101 countsByYear W25077881012017 @default.
- W2507788101 countsByYear W25077881012018 @default.
- W2507788101 countsByYear W25077881012019 @default.
- W2507788101 countsByYear W25077881012020 @default.
- W2507788101 countsByYear W25077881012021 @default.
- W2507788101 countsByYear W25077881012022 @default.
- W2507788101 countsByYear W25077881012023 @default.
- W2507788101 crossrefType "journal-article" @default.
- W2507788101 hasAuthorship W2507788101A5000233630 @default.
- W2507788101 hasAuthorship W2507788101A5005976916 @default.
- W2507788101 hasAuthorship W2507788101A5013924501 @default.
- W2507788101 hasAuthorship W2507788101A5016518691 @default.
- W2507788101 hasAuthorship W2507788101A5027967421 @default.
- W2507788101 hasAuthorship W2507788101A5034532090 @default.
- W2507788101 hasAuthorship W2507788101A5036342781 @default.
- W2507788101 hasAuthorship W2507788101A5047152113 @default.
- W2507788101 hasAuthorship W2507788101A5061761689 @default.
- W2507788101 hasAuthorship W2507788101A5090423367 @default.
- W2507788101 hasBestOaLocation W25077881011 @default.
- W2507788101 hasConcept C111919701 @default.
- W2507788101 hasConcept C187191949 @default.
- W2507788101 hasConcept C41008148 @default.
- W2507788101 hasConcept C60644358 @default.
- W2507788101 hasConcept C70721500 @default.
- W2507788101 hasConcept C71924100 @default.
- W2507788101 hasConcept C86803240 @default.
- W2507788101 hasConceptScore W2507788101C111919701 @default.
- W2507788101 hasConceptScore W2507788101C187191949 @default.
- W2507788101 hasConceptScore W2507788101C41008148 @default.
- W2507788101 hasConceptScore W2507788101C60644358 @default.
- W2507788101 hasConceptScore W2507788101C70721500 @default.
- W2507788101 hasConceptScore W2507788101C71924100 @default.
- W2507788101 hasConceptScore W2507788101C86803240 @default.
- W2507788101 hasFunder F4320320890 @default.
- W2507788101 hasFunder F4320321048 @default.
- W2507788101 hasFunder F4320321181 @default.
- W2507788101 hasFunder F4320321454 @default.
- W2507788101 hasFunder F4320321672 @default.
!["Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta‐analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote‐counting method to perform a semiquantitative meta‐analysis of metabolites in tumor tissue and blood. This analysis confirmed well‐known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta‐analyses of CMP studies, calling for improved standardization of metabolomics studies.![][1] The results of clinical metabolic profiling studies in cancer were curated and a meta‐analysis was subsequently performed to identify deregulated metabolites in blood, tissue, and urine.EMBO Mol Med (2016) 8: 1134–1142 [1]: /embed/graphic-1.gif"](?object=%22Cancer%20cell%20metabolism%20has%20received%20increasing%20attention.%20Despite%20a%20boost%20in%20the%20application%20of%20clinical%20metabolic%20profiling%20(CMP)%20in%20cancer%20patients%2C%20a%20meta%E2%80%90analysis%20has%20not%20been%20performed.%20The%20primary%20goal%20of%20this%20study%20was%20to%20assess%20whether%20public%20accessibility%20of%20metabolomics%20data%20and%20identification%20and%20reporting%20of%20metabolites%20were%20sufficient%20to%20assess%20which%20metabolites%20were%20consistently%20altered%20in%20cancer%20patients.%20We%20therefore%20retrospectively%20curated%20data%20from%20CMP%20studies%20in%20cancer%20patients%20published%20during%205%20recent%20years%20and%20used%20an%20established%20vote%E2%80%90counting%20method%20to%20perform%20a%20semiquantitative%20meta%E2%80%90analysis%20of%20metabolites%20in%20tumor%20tissue%20and%20blood.%20This%20analysis%20confirmed%20well%E2%80%90known%20increases%20in%20glycolytic%20metabolites%2C%20but%20also%20unveiled%20unprecedented%20changes%20in%20other%20metabolites%20such%20as%20ketone%20bodies%20and%20amino%20acids%20(histidine%2C%20tryptophan).%20However%2C%20this%20study%20also%20highlighted%20that%20insufficient%20public%20accessibility%20of%20metabolomics%20data%2C%20and%20inadequate%20metabolite%20identification%20and%20reporting%20hamper%20the%20discovery%20potential%20of%20meta%E2%80%90analyses%20of%20CMP%20studies%2C%20calling%20for%20improved%20standardization%20of%20metabolomics%20studies.!%5B%5D%5B1%5D%20The%20results%20of%20clinical%20metabolic%20profiling%20studies%20in%20cancer%20were%20curated%20and%20a%20meta%E2%80%90analysis%20was%20subsequently%20performed%20to%20identify%20deregulated%20metabolites%20in%20blood%2C%20tissue%2C%20and%20urine.EMBO%20Mol%20Med%20(2016)%208%3A%201134%E2%80%931142%20%5B1%5D%3A%20%2Fembed%2Fgraphic-1.gif%22){kind=link}